Literature DB >> 6508005

Charcot-Leyden crystal protein and eosinophil granule major basic protein in sputum of patients with respiratory diseases.

P J Dor, S J Ackerman, G J Gleich.   

Abstract

Sputum eosinophilia is characteristic of bronchial asthma, and sputum specimens from patients with asthma contain eosinophil-derived substances including Charcot-Leyden crystals (CLC) and the eosinophil granule major basic protein (MBP). Prior observations have indicated that an elevated sputum level of MBP is associated with asthma. To determine whether CLC protein was also elevated in asthma, we measured by specific radioimmunoassays the quantities of MBP and CLC protein in sputum specimens from 106 consecutive patients with various respiratory diseases and in sputum specimens from 10 patients hospitalized for asthma. The CLC protein was detected in all sputum samples, and the levels in the 116 samples averaged 3.5 micrograms/ml (range, 0.01 to 25 micrograms/ml). The CLC protein was significantly elevated in sputum specimens from patients with acute asthma and from patients with certain other respiratory diseases when associated with bronchopulmonary infection. In contrast, MBP levels in the 116 samples averaged 0.32 micrograms/ml (range, 0.01 to 8.8 micrograms/ml) and were significantly elevated only in patients with asymptomatic or acute asthma. Sputum MBP was not elevated in patients with bronchopulmonary infections unless acute asthma was also present. Thus, an elevated sputum MBP level was specifically associated with asthma, whereas an elevated CLC protein level was associated with both asthma and with bronchopulmonary infection in certain patient groups.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508005     DOI: 10.1164/arrd.1984.130.6.1072

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  16 in total

Review 1.  Galectins in parasite infection and allergic inflammation.

Authors:  Anna R Young; Els N Meeusen
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

2.  Charcot-Leyden crystal protein/galectin-10 is a surrogate biomarker of eosinophilic airway inflammation in asthma.

Authors:  Sharmilee M Nyenhuis; Preeth Alumkal; Jian Du; Brian T Maybruck; Mark Vinicky; Steven J Ackerman
Journal:  Biomark Med       Date:  2019-06-03       Impact factor: 2.851

Review 3.  What targeting eosinophils has taught us about their role in diseases.

Authors:  Bruce S Bochner; Gerald J Gleich
Journal:  J Allergy Clin Immunol       Date:  2010-07       Impact factor: 10.793

4.  RNA Seq profiling reveals a novel expression pattern of TGF-β target genes in human blood eosinophils.

Authors:  Zhong-Jian Shen; Jie Hu; Stephane Esnault; Igor Dozmorov; James S Malter
Journal:  Immunol Lett       Date:  2015-06-22       Impact factor: 3.685

Review 5.  Inflammatory processes in bronchial asthma.

Authors:  R Beasley; W Roche; S T Holgate
Journal:  Drugs       Date:  1989       Impact factor: 9.546

Review 6.  Strategies in managing asthma.

Authors:  A F Barker
Journal:  West J Med       Date:  1989-03

Review 7.  Cellular and immunological markers of allergic and intrinsic bronchial asthma.

Authors:  J C Virchow; C Kroegel; C Walker; H Matthys
Journal:  Lung       Date:  1994       Impact factor: 2.584

8.  Charcot-Leyden crystal protein/galectin-10 interacts with cationic ribonucleases and is required for eosinophil granulogenesis.

Authors:  Milica M Grozdanovic; Christine B Doyle; Li Liu; Brian T Maybruck; Mark A Kwatia; Nethaji Thiyagarajan; K Ravi Acharya; Steven J Ackerman
Journal:  J Allergy Clin Immunol       Date:  2020-01-23       Impact factor: 10.793

Review 9.  Galectins: An Ancient Family of Carbohydrate Binding Proteins with Modern Functions.

Authors:  Hans Verkerke; Marcelo Dias-Baruffi; Richard D Cummings; Connie M Arthur; Sean R Stowell
Journal:  Methods Mol Biol       Date:  2022

10.  Galectin-10, a potential biomarker of eosinophilic airway inflammation.

Authors:  Justin C Chua; Jo A Douglass; Andrew Gillman; Robyn E O'Hehir; Els N Meeusen
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.